GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Krystal Biotech KRYS · USD

Health Care · US listing · 🇺🇸 United States

Compare

303.06

+0.72%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

$204.8m

FY2016FY2025

Free cash flow

$188.9m

FY2016FY2025

Shareholders' equity

$1.22bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit$360.4m$270.5m$47.6m−$4.1m−$2.8m−$1.9m−$974,000$886,000−$23,000−$2,000
Research and development$58.0m$53.6m$46.4m$42.5m$27.9m$17.9m$15.6m$7.8m$3.2m$741,000
Operating income$161.3m$65.7m−$109.7m−$145.2m−$68.3m−$33.0m−$22.1m−$11.9m−$4.8m−$1.1m
Net income$204.8m$89.2m$10.9m−$140.0m−$69.6m−$32.2m−$19.1m−$10.9m−$7.9m−$1.1m
Diluted earnings per share6.842.980.38-5.48-3.13-1.61-1.10-0.80-0.77-0.27

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.33bn$1.06bn$818.4m$558.5m$626.3m$310.8m$209.0m$116.1m$50.1m$2.2m
Cash and short-term investments$827.8m$597.5m$532.2m$379.2m$438.1m$271.3m$193.7m$111.8m$49.6m$1.9m
Total liabilities$114.2m$109.5m$39.7m$36.2m$32.7m$18.8m$6.1m$2.9m$640,000$1.9m
Debt$1.8m————————$1.8m
Shareholders' equity$1.22bn$946.4m$778.6m$522.2m$593.6m$292.1m$202.9m$113.2m$49.5m$289,000
Shares outstanding30m30m29m26m22m20m17m14m10m4m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$200.9m$123.4m−$88.8m−$100.6m−$47.9m−$26.1m−$18.7m−$9.4m−$3.9m−$1.3m
Capital spending−$12.0m−$4.2m−$11.8m−$53.0m−$68.3m−$14.8m−$6.4m−$2.2m−$210,000−$15,000
Free cash flow$188.9m$119.2m−$100.6m−$153.5m−$116.3m−$40.9m−$25.1m−$11.7m−$4.1m−$1.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit$112.8m$110.0m$96.2m$92.1m$88.9m$83.2m$86.2m$77.2m
Operating income$58.4m$53.7m$44.4m$41.4m$39.3m$36.2m$41.4m$22.4m
Net income$54.8m$55.9m$51.4m$79.4m$38.3m$35.7m$45.5m$27.2m
Diluted earnings per share1.791.821.722.651.281.191.520.91
Cash from operations$74.0m$80.0m$77.0m$39.0m$52.0m$30.0m$52.0m$58.0m
Capital spending−$3.0m−$7.0m−$2.0m−$1.0m−$1.0m−$6.0m—−$1.0m
Free cash flow$71.0m$73.0m$75.0m$38.0m$51.0m$24.0m—$57.0m
Total assets$1.50bn$1.40bn$1.33bn$1.24bn$1.14bn$1.07bn$1.06bn$982.3m
Cash and short-term investments$845.6m$823.4m$827.8m$731.1m$682.0m$616.8m$597.5m$588.3m
Debt$1.8m$1.8m$1.8m$1.7m$1.6m$1.4m$1.2m$1.3m
Shareholders' equity$1.36bn$1.28bn$1.22bn$1.14bn$1.04bn$984.7m$946.4m$885.8m

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY2016
Gross margin92.6%93.1%93.9%———86.3%——
Operating margin48.7%35.5%-191.8%———-1060.3%——
Net margin52.6%30.7%21.6%———-1060.3%——
Return on equity16.8%9.4%1.4%-26.8%-11.7%-11.0%———
Return on assets15.4%8.4%1.3%-25.1%-11.1%-10.3%———
Free cash flow yield2.2%1.3%-0.8%-0.6%0.3%-0.2%———
Revenue growth33.9%473.0%———————
Earnings growth129.7%715.6%-107.8%101.2%116.3%68.5%———
Current ratio9.95x7.28x17.76x13.30x17.18x17.80x———
Debt to equity0.00x0.00x0.00x0.00x0.00x0.03x———
Equity ratio91.4%89.6%95.1%93.5%94.8%94.0%———
Interest coverage———-23.02x-45.63x-38.66x-10.60x-1.48x-163.29x
R&D as a share of sales14.9%18.4%91.6%———755.7%——
Buybacks as a share of market value-0.2%-3.7%-12.8%-15.1%-10.9%-15.4%———

Average margins

Over each period

1 year3 years5 years10 years
Gross margin92.8%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings36.052.5327.0-14.5-22.3-37.3-50.3-25.9-13.7
Price to sales19.016.170.5————274.5—

Market value over time

29 Sept 2017 to 8 Oct 2026, in USD

$29.9m$10.03bn

Share price return

Finished calendar years

202520242023202220212020201920182017
Return49%31%57%9%18%3%173%137%-17%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.